COMMUNIQUÉS West-GlobeNewswire

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025
15/10/2025
PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, [...]
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
15/10/2025
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced [...]
Sienna Announces October Dividend
15/10/2025
MARKHAM, Ontario, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
Chiesi Announces FDA Acceptance of New Drug Application for its Triple Combination Inhaler for the Maintenance Treatment of Asthma
15/10/2025
Asthma remains a significant health burden in the U.S., with more than 60% of adults continuing to experience frequent symptoms despite the availability of many treatments. 1 Chiesi’s single inhaler triple therapy ( [...]
Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio
15/10/2025
Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year . New, potentially best-in-class ADC is [...]
Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
15/10/2025
NMPA’s response is based on the Phase 3 DRAGON interim analysis results Topline final data expected in Q4 2025 SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug [...]
Extendicare Announces October 2025 Dividend of C$0.042 per Share
15/10/2025
MARKHAM, Ontario, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of [...]
Turn Therapeutics Appoints Dr. Kent Kester to Board of Directors
15/10/2025
Seasoned clinician and R&D leader brings extensive experience in translational medicine, drug development, and infectious disease research WESTLAKE VILLAGE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Turn [...]
Step Pharma announces completion of €38 million Series C financing
15/10/2025
Financing will support the Company’s ongoing clinical development of its lead asset, dencatistat, across multiple indications Round led by new investor V-Bio Ventures, with participation from existing investors Pontifax [...]
Daxor’s New BVA Technology To Be Showcased At MedAxiom CV Transforum Fall '25
15/10/2025
OAK RIDGE, Tenn., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the MedAxiom Cardiovascular (CV) [...]
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
15/10/2025
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report [...]
Rezolute to Participate in Upcoming Investor Conferences
15/10/2025
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
Verano Announces Grand Opening of Zen Leaf Antwerp in 19th Century Historic Ohio Train Depot, Offering Cannabis Consumers One of the Most Unique Dispensary Shopping Experiences in the U.S.
15/10/2025
Zen Leaf is Located in Antwerp’s Norfolk & Western Train Depot Originally Built in 1880 and Listed on the National Register of Historic Places Located at 503 W. River Street , Zen Leaf Antwerp is situated less than [...]
Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain Platform
15/10/2025
- Financing led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations, and E1 Ventures - Proceeds to accelerate strategic partnerships and internal CNS development programs to [...]
Algernon Pharmaceuticals Completes Name Change to Algernon Health
15/10/2025
VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it has [...]
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
15/10/2025
SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by [...]
Transpire Bio Granted Orphan Drug Designation by the U.S. FDA For Two Rare Diseases
15/10/2025
• TRB-ILD1 granted U.S. Orphan Drug Designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF) • TRB-ONC1 granted U.S. Orphan Drug Designation by the FDA for the treatment of glioblastoma (GBM) [...]
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
15/10/2025
ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
15/10/2025
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883 [...]

Pages